Alexandre Reuben

List of Publications by Year
in descending order

95 papers	14,968 citations	66343 42 h-index	51608 86 g-index
109 all docs	109 docs citations	109 times ranked	21198 citing authors

#	Article	IF	Citations
1	Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Annals of Oncology, 2022, 33, 42-56.	1.2	56
2	Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunology Research, 2022, 10, 259-271.	3.4	10
3	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
4	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 172.	8.6	2
5	Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Cancer Discovery, 2022, 12, 2330-2349.	9.4	22
6	Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 90-101.	5.6	22
7	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. Journal of Thoracic Oncology, 2021, 16, 127-139.	1.1	48
8	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nature Communications, 2021, 12, 687.	12.8	30
9	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	30.7	357
10	Identification of bacteria-derived HLA-bound peptides in melanoma. Nature, 2021, 592, 138-143.	27.8	187
11	Global analysis of shared TÂcell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity, 2021, 54, 586-602.e8.	14.3	80
12	Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes. Frontiers in Immunology, 2021, 12, 659625.	4.8	6
13	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600.	1.1	62
14	Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model. Cancers, 2021, 13, 2293.	3.7	6
15	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nature Communications, 2021, 12, 2722.	12.8	74
16	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	30.7	216
17	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
18	Multiomics Analysis Reveals Distinct Immunogenomic Features of Lung Cancer with Ground-Glass Opacity. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1180-1192.	5.6	37

#	Article	IF	Citations
19	Deep learning-based prediction of the T cell receptorâ€“antigen binding specificity. Nature Machine Intelligence, 2021, 3, 864-875.	16.0	99
20	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf -mutated melanoma. OncoImmunology, 2021, 10, 1992880.	4.6	7
21	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications, 2021, 12, 6655.	12.8	24
22	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nature Communications, 2021, 12, 7081.	12.8	16
23	Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 349-357.	0.8	27
24	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. Clinical Cancer Research, 2020, 26, 2908-2920.	7.0	30
25	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. , 2020, 8, e000960.		31
26	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunology Research, 2020, 8, 1365-1380.	3.4	37
27	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clinical Cancer Research, 2020, 26, 5477-5486.	7.0	15
28	Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biology, 2020, 21, 271.	8.8	36
29	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. , 2020, 8, e000405.		33
30	Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Science Translational Medicine, 2020, 12, .	12.4	108
31	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer, 2020, 146, 303-309.	2.0	2
32	Immuno-genomic landscape of osteosarcoma. Nature Communications, 2020, 11, 1008.	12.8	143
33	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	27.8	1,421
34	18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1519-1534.	4.2	21
35	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2020, 140, 2146-2156.e4.	0.7	14
36	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nature Communications, 2020, 11, 1839.	12.8	15

#	Article	IF	Citations
37	Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clinical Cancer Research, 2020, 26, 1258-1266.	7.0	115
38	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1449-1459.	1.1	109
39	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	12.8	140
40	Discovery of a novel shared tumor antigen in human lung cancer.. Journal of Clinical Oncology, 2020, 38, 3087-3087.	1.6	0
41	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nature Communications, 2019, 10, 2978.	12.8	91
42	Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Annals of Oncology, 2019, 30, 1521-1530.	1.2	94
43	Combination antiâ€“CTLA-4 plus antiâ€“PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22699-22709.	7.1	226
44	A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clinical Cancer Research, 2019, 25, 6429-6442.	7.0	61
45	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1021-1031.	1.1	79
46	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research, 2019, 7, 1025-1035.	3.4	70
47	Gene expression profiling of lichenoid dermatitis immuneâ€related adverse event from immune checkpoint inhibitors reveals increased CD14⁺ and CD16⁺ monocytes driving an innate immune response. Journal of Cutaneous Pathology, 2019, 46, 627-636.	1.3	27
48	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discovery, 2019, 9, 628-645.	9.4	231
49	P2.04-19 Neoadjuvant Chemotherapy Is Associated with Immunogenic Cell Death and Increased T Cell Infiltration in Early-Stage NSCLC. Journal of Thoracic Oncology, 2019, 14, S715.	1.1	0
50	Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9017-9017.	1.6	9
51	Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, e14047-e14047.	1.6	1
52	Characterization of Changes in the T-Cell Receptor Repertoire in Patients with Acute Myeloid Leukemia with Durable Remission Following Allogeneic Stem Cell Transplant. Blood, 2019, 134, 5186-5186.	1.4	0
53	The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell, 2018, 33, 570-580.	16.8	911
54	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. OncoImmunology, 2018, 7, e1423172.	4.6	25

#	Article	IF	Citations
55	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2018, 19, 181-193.	10.7	233
56	Gut microbiome modulates response to antiâ€“PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103.	12.6	3,126
57	P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S733-S734.	1.1	3
58	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654.	30.7	592
59	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell, 2018, 175, 998-1013.e20.	28.9	1,260
60	Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discovery, 2018, 8, 1366-1375.	9.4	80
61	24 Combined analysis of antigen presentation and T cell recognition reveals restricted immune responses in melanoma. ESMO Open, 2018, 3, A11.	4.5	1
62	Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. Frontiers in Immunology, 2018, 9, 946.	4.8	19
63	Abstract 4686: T cell repertoire evolution from the normal lung to invasive lung adenocarcinoma. , 2018, , .		2
64	Association of the T-cell receptor landscape with survival in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 140-140.	1.6	4
65	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, .	12.4	689
66	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. Journal of Experimental Medicine, 2017, 214, 1691-1710.	8.5	71
67	Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?. Clinical Cancer Research, 2017, 23, 327-329.	7.0	1
68	Interaction of molecular alterations with immune response in melanoma. Cancer, 2017, 123, 2130-2142.	4.1	24
69	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	3.8	120
70	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science, 2017, 357, 1156-1160.	12.6	1,059
71	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 2017, 7, 1088-1097.	9.4	160
72	Toward a Molecular-Genetic Classification of Spitzoid Neoplasms. Clinics in Laboratory Medicine, 2017, 37, 431-448.	1.4	29

#	Article	IF	Citations
73	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. OncoImmunology, 2017, 6, e1361097.	4.6	50
74	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. OncoImmunology, 2017, 6, e1321187.	4.6	45
75	OA 13.05 Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues. Journal of Thoracic Oncology, 2017, 12, S1780.	1.1	3
76	The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune system. Immunity, Inflammation and Disease, 2017, 5, 218-232.	2.7	40
77	Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer Journal (Sudbury, Mass), 2016, 22, 138-146.	2.0	36
78	Monitoring immune responses in the tumor microenvironment. Current Opinion in Immunology, 2016, 41, 23-31.	5.5	96
79	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Current Oncology Reports, 2016, 18, 42.	4.0	54
80	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitorâ€“Refractory Metastatic Melanoma. JAMA Oncology, 2016, 2, 1056.	7.1	41
81	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. Clinical Cancer Research, 2016, 22, 5553-5563.	7.0	96
82	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	9.4	785
83	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology, 2016, 5, e1136044.	4.6	55
84	Working with Human Tissues for Translational Cancer Research. Journal of Visualized Experiments, 2015, , .	0.3	2
85	Update on use of aldesleukin for treatment of high-risk metastatic melanoma. ImmunoTargets and Therapy, 2015, 4, 79.	5.8	21
86	Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. Clinical Cancer Research, 2015, 21, 3102-3104.	7.0	27
87	T lymphocyte-derived TNF and IFN-Î³ repress HFE expression in cancer cells. Molecular Immunology, 2015, 65, 259-266.	2.2	5
88	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Seminars in Oncology, 2015, 42, 601-616.	2.2	139
89	Raising the bar: optimizing combinations of targeted therapy and immunotherapy. Annals of Translational Medicine, 2015, 3, 272.	1.7	0
90	RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma. Journal of Pigmentary Disorders, 2014, 01, .	0.2	0

#	Article	IF	Citations
91	Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. OncoImmunology, 2014, 3, e954956.	4.6	19
92	The WT hemochromatosis protein HFE inhibits CD8⁺ Tâ€lymphocyte activation. European Journal of Immunology, 2014, 44, 1604-1614.	2.9	20
93	Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biology and Medicine, 2014, 11, 237-46.	3.0	64
94	Polyfunctionality of a DKK1 self-antigen-specific CD8+ T lymphocyte clone in lung cancer. Cancer Immunology, Immunotherapy, 2011, 60, 1119-1125.	4.2	1
95	Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrobial Agents and Chemotherapy, 1989, 33, 1647-1649.	3.2	89